keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson

keyword
https://www.readbyqxmd.com/read/28527315/longitudinal-decline-in-speech-production-in-parkinson-s-disease-spectrum-disorders
#1
Sharon Ash, Charles Jester, Collin York, Olga L Kofman, Rachel Langey, Amy Halpin, Kim Firn, Sophia Dominguez Perez, Lama Chahine, Meredith Spindler, Nabila Dahodwala, David J Irwin, Corey McMillan, Daniel Weintraub, Murray Grossman
We examined narrative speech production longitudinally in non-demented (n=15) and mildly demented (n=8) patients with Parkinson's disease spectrum disorder (PDSD), and we related increasing impairment to structural brain changes in specific language and motor regions. Patients provided semi-structured speech samples, describing a standardized picture at two time points (mean±SD interval=38±24months). The recorded speech samples were analyzed for fluency, grammar, and informativeness. PDSD patients with dementia exhibited significant decline in their speech, unrelated to changes in overall cognitive or motor functioning...
May 17, 2017: Brain and Language
https://www.readbyqxmd.com/read/28527233/effect-of-expiratory-muscle-strength-training-intervention-on-the-maximum-expiratory-pressure-and-quality-of-life-of-patients-with-parkinson-disease
#2
Yu-Chi Kuo, Jomei Chan, Yu-Ping Wu, Jeffrey R Bernard, Yi-Hung Liao
PURPOSE: The purpose of this study was to investigate the effects of 4-weeks expiratory muscle strength training (EMST) on the maximum expiratory pressure (PEmax) and quality of life (QoL) in patients with Parkinson disease (PD). METHODS: Thirteen outpatients diagnosed with PD participated in this study, and were assigned into either a 5DE training group (5DE group; n = 4; 75% PEmax for 5-d/wk), 3DE training group (3DE group; n = 5; 75% PEmax for 3-d/wk) and control group (3DC group; n = 4; 0% PEmax for 3-d/wk) by matching their Hoehn and Yahr scale, genders, and age...
May 13, 2017: NeuroRehabilitation
https://www.readbyqxmd.com/read/28527232/three-dimensional-evaluation-of%C3%A2-postural%C3%A2-stability-in-parkinson-s-disease-with-mobile-technology
#3
Sarah J Ozinga, Mandy Miller Koop, Susan M Linder, Andre G Machado, Tanujit Dey, Jay L Alberts
BACKGROUND: Postural instability is a hallmark of Parkinson's disease. Objective metrics to characterize postural stability are necessary for the development of treatment algorithms to aid in the clinical setting. OBJECTIVE: The aim of this project was to validate a mobile device platform and resultant three-dimensional balance metric that characterizes postural stability. METHODS: A mobile Application was developed, in which biomechanical data from inertial sensors within a mobile device were processed to characterize movement of center of mass in the medial-lateral, anterior-posterior and trunk rotation directions...
May 13, 2017: NeuroRehabilitation
https://www.readbyqxmd.com/read/28527231/nordic-walking-improves-trunk-stability-and%C3%A2-gait-spatial-temporal-characteristics-in%C3%A2-people-with-parkinson-disease
#4
Marie-Anne Gougeon, Lei Zhou, Julie Nantel
BACKGROUND: This study aimed to assess the effect of walking with Nordic walking (NW) poles on postural stability and gait spatial-temporal characteristics in individuals with PD and to determine the cognitive load associated operating the poles. METHODS: Twelve individuals with PD (age: 61.6±11.7) were asked to perform four 90 s walking trials; with/without poles and with/without verbal fluency task (category fluency) after a 6-week independent NW training. We assessed gait spatial-temporal characteristics, and trunk postural stability using the APDM accelerometry system...
May 13, 2017: NeuroRehabilitation
https://www.readbyqxmd.com/read/28527219/tmem230-accumulation-in-granulovacuolar-degeneration-bodies-and-dystrophic-neurites-of-alzheimer-s-disease
#5
Sandra L Siedlak, Yingfei Jiang, Mikayla L Huntley, Luwen Wang, Ju Gao, Fei Xie, Jingyi Liu, Bo Su, George Perry, Xinglong Wang
Transmembrane Protein 230 (TMEM230) is a newly identified protein associated with Parkinson's disease (PD) found in Lewy bodies and Lewy neurites of patients with PD or dementia with Lewy body disease. However, TMEM230 has not yet been investigated in the most common neurodegenerative disorder, Alzheimer's disease (AD). Here, we demonstrate that the expression of TMEM230 is specifically increased in neurons in AD patients. Importantly, both granulovacuolar degeneration (GVD) and dystrophic neurites (DNs), two prominent characteristic pathological structures associated with AD, contain TMEM230 aggregates...
May 17, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28527045/amyotrophic-lateral-sclerosis-like-superoxide-dismutase-1-proteinopathy-is-associated-with-neuronal-loss-in-parkinson-s-disease-brain
#6
Benjamin G Trist, Katherine M Davies, Veronica Cottam, Sian Genoud, Richard Ortega, Stéphane Roudeau, Asuncion Carmona, Kasun De Silva, Valerie Wasinger, Simon J G Lewis, Perminder Sachdev, Bradley Smith, Claire Troakes, Caroline Vance, Christopher Shaw, Safa Al-Sarraj, Helen J Ball, Glenda M Halliday, Dominic J Hare, Kay L Double
Neuronal loss in numerous neurodegenerative disorders has been linked to protein aggregation and oxidative stress. Emerging data regarding overlapping proteinopathy in traditionally distinct neurodegenerative diseases suggest that disease-modifying treatments targeting these pathological features may exhibit efficacy across multiple disorders. Here, we describe proteinopathy distinct from classic synucleinopathy, predominantly comprised of the anti-oxidant enzyme superoxide dismutase-1 (SOD1), in the Parkinson's disease brain...
May 19, 2017: Acta Neuropathologica
https://www.readbyqxmd.com/read/28526930/micrornas-in-parkinson-s-disease
#7
REVIEW
Abhishek Singh, Dwaipayan Sen
Parkinson's disease is the second most common neurodegenerative disease commonly affecting the older population. Loss of dopaminergic neurons in the substantia nigra of brain leads to impairment of motor activities as well as cognitive defects. There are many underlying causes to this disease, both genetic and epigenetic, which are yet to be fully explored. Non-coding RNAs are significant part of our genome and are involved in various cellular processes. MicroRNAs, which are small non-coding RNAs having 20-22 nucleotides, are involved in many underlying mechanisms of pathogenesis of several neurodegenerative diseases including Parkinson's...
May 19, 2017: Experimental Brain Research. Experimentelle Hirnforschung. Expérimentation Cérébrale
https://www.readbyqxmd.com/read/28526642/-asleep-deep-brain-stimulation-surgery-a-critical-review-of-the-literature
#8
REVIEW
Tsinsue Chen, Zaman Mirzadeh, Francisco A Ponce
OBJECTIVE: Although performing deep brain stimulation (DBS) with the patient under general anesthesia without microelectrode recording (MER) or intraoperative test stimulation (ITS) for movement disorders ("asleep" DBS) has become increasingly popular, its feasibility is based on the untested assumption that stereotactic accuracy correlates with positive clinical outcomes. To investigate outcomes after asleep DBS without MER or neurophysiological testing, we reviewed the medical literature on the topic...
May 16, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28526609/effects-of-l-dopa-benserazide-co-treatment-on-colonic-excitatory-cholinergic-motility-and-enteric-inflammation-following-dopaminergic-nigrostriatal-neurodegeneration
#9
C Pellegrini, L Antonioli, R Colucci, E Tirotta, D Gentile, C Ippolito, C Segnani, G Levandis, S Cerri, R F Blandini, E Barocelli, V Ballabeni, N Bernardini, C Blandizzi, M Fornai
INTRODUCTION: The mainstay therapy for Parkinson's disease (PD) relies on L-3,4- dihydroxyphenylalanine (L-DOPA) plus a DOPA-decarboxylase inhibitor. However, their effects on colonic dysmotility and inflammation observed in PD are undetermined. This study examined the effects of L-DOPA plus benserazide (BE) on colonic motility and inflammation in rats with central nigrostriatal dopaminergic denervation. METHODS: Neurodegeneration was induced by 6-hydroxydopamine (6-OHDA) injection into the median forebrain bundle (MFB)...
May 16, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28526576/carvacrol-promotes-neuroprotection-in-the-mouse-hemiparkinsonian-model
#10
L M Dati, H Ulrich, C C Real, Z P Feng, H S Sun, L R Britto
Carvacrol is a monoterpene that has been linked to neuroprotection in several animal models of neurodegeneration, including ischemia, epilepsy and traumatic neuronal injury. In this study, we investigated the effects of carvacrol (i.p.) upon the neurodegeneration induced by 6-hydroxy-dopamine unilateral intrastriatal injections in mice. We have also used the cylinder test to assess the behavioral effects of carvacrol in that model of Parkinsońs disease, and immunoblots to evaluate the levels of caspase-3 and TRPM7, one of major targets of carvacrol...
May 16, 2017: Neuroscience
https://www.readbyqxmd.com/read/28526514/levodopa-has-primarily-negative-influences-on-postural-control-in-patients-with-parkinson-s-disease
#11
Cédrick T Bonnet, Arnaud Delval, Sébastien Szaffarczyk, Luc Defebvre
Patients with Parkinson's disease have better functional status and motor performance under on-drug conditions. However, the administration of levodopa leads to greater postural sway. The present study's primary objective was to determine whether this on-drug problem may be related to a lack of adjustment in postural control mechanisms and body segment rotations. Fourteen patients with Parkinson's disease and 14 controls performed two gaze-shift tasks (40° to the left and 40° to the right, at 0.125 and 0...
May 16, 2017: Behavioural Brain Research
https://www.readbyqxmd.com/read/28526446/thymoquinone-exerts-neuroprotective-effect-in-animal-model-of-parkinson-s-disease
#12
Seyedeh Shohreh Ebrahimi, Shahrbanoo Oryan, Esmael Izadpanah, Kambiz Hassanzadeh
Oxidative stress plays an important role in both the initiation and progression of Parkinson's disease (PD). Rotenone, an environmental toxin, induces oxidative stress and impact mitochondrial dynamics, including fission and fusion. Thymoquinone (TQ) has been reported to have antioxidant and anti-inflammatory characteristics in vitro and in vivo. TQ scavenges free radicals so prevents cell damage against oxidative agents. To evaluate the efficacy of TQ in the management of PD, male Wistar rats (8-10 months) received rotenone...
May 16, 2017: Toxicology Letters
https://www.readbyqxmd.com/read/28526295/large-scale-exploratory-genetic-analysis-of-cognitive-impairment-in-parkinson-s-disease
#13
Ignacio F Mata, Catherine O Johnson, James B Leverenz, Daniel Weintraub, John Q Trojanowski, Vivianna M Van Deerlin, Beate Ritz, Rebecca Rausch, Stewart A Factor, Cathy Wood-Siverio, Joseph F Quinn, Kathryn A Chung, Amie L Peterson-Hiller, Alberto J Espay, Fredy J Revilla, Johnna Devoto, Dora Yearout, Shu-Ching Hu, Brenna A Cholerton, Thomas J Montine, Karen L Edwards, Cyrus P Zabetian
Cognitive impairment is a common and disabling problem in Parkinson's disease (PD). Identification of genetic variants that influence the presence or severity of cognitive deficits in PD might provide a clearer understanding of the pathophysiology underlying this important nonmotor feature. We genotyped 1105 PD patients from the PD Cognitive Genetics Consortium for 249,336 variants using the NeuroX array. Participants underwent assessments of learning and memory (Hopkins Verbal Learning Test-Revised [HVLT-R]), working memory/executive function (Letter-Number Sequencing and Trail Making Test [TMT] A and B), language processing (semantic and phonemic verbal fluency), visuospatial abilities (Benton Judgment of Line Orientation [JoLO]), and global cognitive function (Montreal Cognitive Assessment)...
April 20, 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28526239/cellular-models-as-tools-for-the-study-of-the-role-of-alpha-synuclein-in-parkinson-s-disease
#14
REVIEW
Diana F Lázaro, Maria Angeliki S Pavlou, Tiago Fleming Outeiro
Neurodegenerative diseases are highly debilitating conditions characterised primarily by progressive neuronal loss and impairment of the nervous system. Parkinson's disease (PD) is one of the most common of these disorders, affecting 1-2% of the population above the age of 65. Although the underlying mechanisms of PD have been extensively studied, we still lack a full understanding of the molecular underpinnings of the disease. Thus, the in vitro and in vivo models currently used are able to only partially recapitulate the typical phenotypes of the disease...
May 16, 2017: Experimental Neurology
https://www.readbyqxmd.com/read/28525887/an-updated-meta-analysis-of-amantadine-for-treating-dyskinesia-in-parkinson-s-disease
#15
Min Kong, Maowen Ba, Chao Ren, Ling Yu, Shengjie Dong, Guoping Yu, Hui Liang
In recent years, a few of randomized controlled trials (RCTs) about amantadine for treating dyskinesia in Parkinson's disease (PD) were completed. Here, we conducted a systematic literature review about the clinical research to provide the updated evidence for treating dyskinesia. Electronic search of Medline, PubMed, Cochrane Library, and other databases up to May 2016 for relevant studies was performed. We selected the Unified Parkinson's Disease Rating Scale IV (UPDRS IV) and Dyskinesia Rating Scales (DRS) as efficacy outcomes of amantadine on dyskinesia...
May 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/28523903/dopamine-and-noradrenaline-but-not-serotonin-in-the-human-claustrum-are-greatly-reduced-in-patients-with-parkinson-s-disease-possible-functional-implications
#16
Harald H Sitte, Christian Pifl, Ali H Rajput, Heide Hörtnagl, Junchao Tong, George K Lloyd, Stephen J Kish, Oleh Hornykiewicz
No abstract text is available yet for this article.
May 2017: European Journal of Neuroscience
https://www.readbyqxmd.com/read/28523560/stem-cell-technology-for-epi-genetic-brain-disorders
#17
Renzo J M Riemens, Edilene S Soares, Manel Esteller, Raul Delgado-Morales
Despite the enormous efforts of the scientific community over the years, effective therapeutics for many (epi)genetic brain disorders remain unidentified. The common and persistent failures to translate preclinical findings into clinical success are partially attributed to the limited efficiency of current disease models. Although animal and cellular models have substantially improved our knowledge of the pathological processes involved in these disorders, human brain research has generally been hampered by a lack of satisfactory humanized model systems...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28523558/epigenome-editing-in-the-brain
#18
Pavel Bashtrykov, Albert Jeltsch
Epigenome editing aims for an introduction or removal of chromatin marks at a defined genomic region using artificial EpiEffectors resulting in a modulation of the activity of the targeted functional DNA elements. Rationally designed EpiEffectors consist of a targeting DNA-binding module (such as a zinc finger protein, TAL effector, or CRISPR/Cas complex) and usually, but not exclusively, a catalytic domain of a chromatin-modifying enzyme. Epigenome editing opens a completely new strategy for basic research of the central nervous system and causal treatment of psychiatric and neurological diseases, because rewriting of epigenetic information can lead to the direct and durable control of the expression of disease-associated genes...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28523556/epigenetics-in-parkinson-s-disease
#19
Maria Angeliki S Pavlou, Tiago Fleming Outeiro
Parkinson's disease (PD) is a highly complex neurodegenerative disorder with a multifactorial origin. Although several cellular mechanisms and genes have been implicated in the onset and progression of the disease, the precise molecular underpinnings of the disease remain unclear. In this context, epigenetic modulation of gene expression by environmental factors is emerging as an important mechanism in PD and in other neurodegenerative disorders. Thus, epigenetic mechanisms, such as DNA methylation, histone modifications and altered microRNA expression, have been under intense investigation due to their possible involvement in PD...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28523458/the-respiratory-chain-inhibitor-rotenone-affects-peroxisomal-dynamics-via-its-microtubule-destabilising-activity
#20
Josiah B Passmore, Sonia Pinho, Maria Gomez-Lazaro, Michael Schrader
Peroxisomes and mitochondria in mammalian cells are closely linked subcellular organelles, which maintain a redox-sensitive relationship. Their interplay and role in ROS signalling are supposed to impact on age-related and degenerative disorders. Whereas the generation of peroxisome-derived oxidative stress can affect mitochondrial morphology and function, little is known about the impact of mitochondria-derived oxidative stress on peroxisomes. Here, we investigated the effect of the mitochondrial complex I inhibitor rotenone on peroxisomal and mitochondrial membrane dynamics...
May 18, 2017: Histochemistry and Cell Biology
keyword
keyword
2250
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"